Abstract
The oceans are a source of a large group of structurally unique natural products that are mainly found in invertebrates such as sponges, tunicates, bryozoans, and molluscs. It is interesting to note that the majority of marine compounds currently in clinical trials or under preclinical evaluation are produced by these species rather than as secondary metabolites by marine algae [1]. Through the combined efforts of marine natural products chemists and pharmacologists a number of promising compounds have been identified that are either already at advanced stages of clinical trials such as the new anti-cancer drug marine alkaloid ecteinascidin 743 [2], or have been selected as promising candidates for extended preclinical evaluation [3]. This is the case for conotoxins, (Table 1) where a number of conopeptides are currently being developed as analgesics for the treatment of neuropathic pain.
Keywords: neuropathic pain, antidepressant, new antidepressant drugs, antinociception, mechanism of action, clinical trials
Mini-Reviews in Medicinal Chemistry
Title: Drugs From the Sea: Conotoxins as Drug Leads for Neuropathic Pain and Other Neurological Conditions
Volume: 3 Issue: 7
Author(s): D. Alonso, Z. Khalil, N. Satkunanthan and B. G. Livett
Affiliation:
Keywords: neuropathic pain, antidepressant, new antidepressant drugs, antinociception, mechanism of action, clinical trials
Abstract: The oceans are a source of a large group of structurally unique natural products that are mainly found in invertebrates such as sponges, tunicates, bryozoans, and molluscs. It is interesting to note that the majority of marine compounds currently in clinical trials or under preclinical evaluation are produced by these species rather than as secondary metabolites by marine algae [1]. Through the combined efforts of marine natural products chemists and pharmacologists a number of promising compounds have been identified that are either already at advanced stages of clinical trials such as the new anti-cancer drug marine alkaloid ecteinascidin 743 [2], or have been selected as promising candidates for extended preclinical evaluation [3]. This is the case for conotoxins, (Table 1) where a number of conopeptides are currently being developed as analgesics for the treatment of neuropathic pain.
Export Options
About this article
Cite this article as:
Alonso D., Khalil Z., Satkunanthan N. and Livett G. B., Drugs From the Sea: Conotoxins as Drug Leads for Neuropathic Pain and Other Neurological Conditions, Mini-Reviews in Medicinal Chemistry 2003; 3 (7) . https://dx.doi.org/10.2174/1389557033487746
DOI https://dx.doi.org/10.2174/1389557033487746 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of MicroPET in Basic Epilepsy Research
Current Medical Imaging Synthesis and Pharmacological Screening of Novel 1,3-Disubstituted 5-Pyrazolones as Anticonvulsant Agents
Current Bioactive Compounds Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Extrasynaptic GABA and Glutamate Receptors in Epilepsy
CNS & Neurological Disorders - Drug Targets The Use of Microarrays to Study Childhood Developmental Brain Disorders
Current Genomics Occurrence of DAT1 (VNTR) Polymorphism in Individuals with HIV Infection
Current Pharmacogenomics and Personalized Medicine Are Selenoproteins Important for the Cancer Protective Effects of Selenium?
Current Nutrition & Food Science Kappa Receptor Bivalent Ligands
Current Topics in Medicinal Chemistry Structure-Based Design of Benzimidazole Sugar Conjugates: Synthesis, SAR and In Vivo Anti-inflammatory and Analgesic Activities
Medicinal Chemistry Schiff Bases of Benzothiazol-2-ylamine and Thiazolo[5,4-b] pyridin-2-ylamine as Anticonvulsants: Synthesis, Characterization and Toxicity Profiling*
Central Nervous System Agents in Medicinal Chemistry <i>Cannabis Sativa</i> L. Flower and Bud Extracts Inhibited <i>In vitro</i> Cholinesterases and β-Secretase Enzymes Activities: Possible Mechanisms of Cannabis Use in Alzheimer Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Oxidative Stress in the Molecular Mechanism of Pathogenesis at Different Diseased States of Organism in Clinics and Experiment
Current Drug Targets - Inflammation & Allergy Nuezhenide Exerts Anti-Inflammatory Activity through the NF-κB Pathway
Current Molecular Pharmacology GluN2B/N-methyl-D-aspartate Receptor Antagonists: Advances in Design, Synthesis, and Pharmacological Evaluation Studies
CNS & Neurological Disorders - Drug Targets Dynamic Expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the Rat Pilocarpine Model and Temporal Lobe Epilepsy Patients
CNS & Neurological Disorders - Drug Targets Neural Progenitors and HIV-1- Associated Central Nervous System Disease in Adults and Children
Current HIV Research Assessing Glutamatergic Function and Dysfunction in Peripheral Tissues
Current Medicinal Chemistry Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective
Current Drug Metabolism Targeting Microglial Polarization to Improve TBI Outcomes
CNS & Neurological Disorders - Drug Targets The Metabolism of Methazolamide - Identification of Metabolites in Guinea Pig Urine
Drug Metabolism Letters